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Abstract 
Monoclonal  antibodies  developed  against  immunogenic  proteins  (Tumor  Specific  Anti-
gens/TSA’s) that are expressed in human cancers, display a unique behavioral pattern. They 
appear to serve in a dual role. This includes the early recognition of these immunogenic 
membrane proteins that can serve as diagnostic markers, and the targeting of such markers 
for the destruction of the tumor, primarily thru ADCC.  
The  monoclonals  (mAbs)  that  we  have  developed  against  specific  immunogenic  tumor 
membrane proteins have been studied in detail. These tumor proteins, when first defined, 
were referred to as tumor associated antigens. With the ability of the mAbs to demonstrate 
therapeutic antitumor activity in those patients with relatively advanced malignancies, the 
term tumor specific was introduced. Monoclonals that we were able to develop from tumor 
specific proteins derived from colon and pancreas cancer were found capable of targeting 
those tumors to induce apoptosis. We were also able to define immunogenic membrane 
proteins from lung (squamous and adenoCa) as well as prostate neoplasms. Monoclonals 
developed from these tumor antigens are in the initial phases of investigation with regard to 
their specificity and antitumor activity.  
Mabs capable of targeting the malignancies noted above were produced following immuni-
zation of BALBc mice with the Tumor Specific Antigens. The hybridomas that were screened 
and found to express the antibodies of interest appeared for the most part as IgG2a’s. It 
became apparent after a short period of time that stability of the Fab CDR loops as well as the 
therapeutic efficacy of the hybridoma mAbs could be lost. Stability was achieved by chime-
rization and or humanization. The resulting mAbs were found to switch their isotypes to an 
IgG1 subsequent to chimerization and or humanization, when expressed in CHO cells. The 
monoclonals, so produced, were not only more efficient in controlling tumor growth but 
minimized the development of a HAMA response. 
Because of 1) the specificity of this group of monoclonal antibodies in targeting well defined 
immunogenic proteins that were expressed on the tumor cell membrane,2) their lack of cross 
reactivity to normal tissue, 3) relatively low toxicity when delivered intravenously, 4) rapid 
targeting of tumor cell populations (4-6 hrs in vitro) and their 5) ability to destroy xenograft 
transplants (in vivo) within days of delivery, these mAbs were felt to be ideal for possible use 
in the treatment of patients with recurrent and or metastatic tumors.  
Initial clinical studies have been planned for following the filing of an IND. It is required by FDA 
that the potential effects of tumor control and toxicity be defined using the naked antibodies 
produced under GMP conditions, In those situations where patients with recurrent malig-
nancies are to be studied we have come to realize that a number of factors can influence the 
response to monoclonal therapy. This includes the amount of shed antigen in the serum at the 
time of treatment that could initiate immune complex formation as well as the shedding of Journal of Cancer 2010, 1 
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inhibitory material into the serum possibly effecting an immune response. As such we plan to 
eventually employ the therapeutic mAbs in combination with chemotherapy as a means of 
enhancing the immunogenicity of the tumor system being treated and to possibly weaken the 
malignant growth for easier destruction by the mAb. We will also look at the combination of 
mAbs with immunostimulants such as GMCSF and IL-2 (fusion proteins) and eventual con-
jugation of the mAbs with alpha and possibly B-emitters to help in targeting bystander cells. 
The present paper reviews the potential therapeutic value of such mAbs in the treatment of 
recurrent malignancies, especially those having failed chemotherapy in established clinical 
trials. 
Key words: Monoclonal antibodies, hybridomas, chimeric antibodies, ADCC, apoptosis, tumor 
specific antigens (TSA). 
1. Introduction 
Based on  our experience with  the use of  com-
mercial monoclonal antibodies (mAbs) employed in 
therapeutic  situations  for  managing  metastatic  ma-
lignancies, especially those targeting growth factors, 
these  monoclonals  appear  to  have  played a limited 
role in controlling the spread of established tumors. 
Those  growth  factors  presently  being  targeted  by 
mAbs such as Erbitux, Vectibix and Avastin, however, 
are not only seen in the malignant state but are also 
expressed on the surface of many normal tissues, i.e. 
skin, bowel. Growth factors are essentially none im-
munogenic, do not shed from the cells that express 
them and are not recognized by the host. The mAbs, 
that have therefore been commercially developed and 
directed against such growth factors, appear to have 
limited therapeutic value and do demonstrate occa-
sional  adverse  responses  when  delivered  intrave-
nously.  
The newer classes of mAbs that we are devel-
oping are, as noted above, directed against immuno-
genic tumor specific antigens (TSA’s) present on the 
surface of tumor cells and absent in normal adjacent 
tissue. Shedding of these TSA antigens into the serum 
does occur, but to a limited degree. This is due to the 
low level of TSA expression within the cytoplasm and 
secondarily to what is chaperoned to the cell mem-
brane where shedding occurs into the serum as po-
tential tumor markers. In contrast, epidermal growth 
factors which are present in normal as well as malig-
nant cells, are not immunogenic and do not shed into 
serum. The host does recognize shed TSA, tending to 
produce  circulating  monoclonals  (mAb1)  with  low 
levels of ADCC (Antibody Dependent Cell Cytotoxic-
ity),  immune  complexes  as  well  as  circulating  an-
ti-TSA  antibodies  (mAb2  anti-idiotypes).  A  conse-
quence of this phenomenon is a low level of humoral 
and cell mediated immunity at the level of what we 
term “tumor surveillance”. The existence of circulat-
ing mAbs, anti-TSA Abs and cytotoxic T-cells are not 
present at a significant level however, to induce con-
tinued apoptosis of developing tumor. They do help 
in minimizing the rate of tumor expression early in 
the  clinical  course  of  disease.  Without  therapeutic 
intervention tumor spread does occur. By raising the 
titer of circulating antibodies to those levels needed to 
reach threshold therapeutic levels by IV administra-
tion,  even  without  directly  enhancing  levels  of  cell 
mediated cytotoxicity, we can anticipate obtaining a 
desired clinical response.  
The mAbs that we have developed via immuni-
zation of BALBc mice and which have derived from 
functional hybridomas and secondarily thru expres-
sion  in  the  chimeric  version  in  CHO,  appear  to 
represent  a  new  and  potentially  effective  group  of 
IgG’s. They offer an alternative approach for treating 
metastatic  malignancies  alone  and  in  combination 
with other antitumor agents. These same mAbs, ex-
pressed as chimeric or humanized mAbs, when given 
intravenously in high therapeutic doses, can initiate 
tumor destruction within hours of IV administration. 
They circulate with a half life exceeding 10 days and 
show a localization index of better than 10:1, where 
the concentration of the mAb fixed to the tumor is 
tenfold or greater than what remains in circulation.  
In the face of progressive and metastatic disease 
that has failed to respond to chemotherapy, few ap-
proaches are available to reverse or control the disease 
process. Specific active immunotherapy with vaccines 
from which the above mAbs are derived, is not a via-
ble  option  in  such  clinical  situations.  The  optimum 
immunologic response to such vaccines (inducing cell 
mediated and humoral immunity) occurs during a 4-6 
month period of time following completion of immu-
nization  (4).  This  interval  is  too  long  to  anticipate 
seeing  a  therapeutic  response  in  patients  with  ad-
vanced  disease.  The  existence  of  a  more  advanced 
malignant  state  usually  has  progressed  in  terms  of 
tumor volume during this period of time and has been 
shown to have expressed a number of factors capable 
of suppressing the immune response (immunological Journal of Cancer 2010, 1 
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escape) (5). Passive immunization with a therapeutic 
monoclonal  antibody  which  works  within  hours  of 
delivery  becomes  the  method  of  choice  in  such  in-
stances.  
Following our early vaccine studies in high risk 
tumor  patients  using  TSA  vaccines,  the  end  results 
appeared to demonstrate a marked enhancement in 
survival  approximating  a  three-fold  increase  over 
controls during a five to seven year period of time. A 
significant finding seen among the long term survi-
vors in the above mentioned clinical trials was a high 
serum titer of IgG1 directed against the tumor anti-
gen. These elevated IgG levels lasted from 5 to 10 or 
more years and paralled the diminution in a delayed 
cutaneous hypersensitivity response to skin test dose 
of  antigen.  In  those  patients  having  received  TSA 
immunization and who had failed therapy showing 
evidence  of  recurrence  of  tumor  within  a  year  of 
treatment, it became apparent that there was an innate 
inability to produce and maintain high levels of the 
anti-tumor IgG. This set the stage for looking into the 
development of the antitumor IgG’s as potential mo-
noclonal  therapeutic  agents  to  be  used  in  patients 
with  advanced,  recurrent  and  possibly  metastatic 
tumor (6).  
Development of hybridomas following inocula-
tion of BALB/c mice with defined human TSA’s i.e 
those immunized with colon or lung TSA, confirmed 
that the resulting murine mAb’s were capable of in-
ducing marked destruction of specific tumors both in 
vivo  and  in  vitro.  Chimerization  of  these  murine 
mAbs  demonstrated  an  enhancement  in  antitumor 
effect because of the presence of the human Fc portion 
of the IgG1 molecule which contains NK cell recep-
tors.  
Those  studies  that  followed,  were  designed  to 
characterize the possible effectiveness of our TSA de-
rived  mAb’s  as  potential  therapeutic  agents  in  pa-
tients  with  advanced  disease,  especially  in  those 
having  failed  chemotherapy  and  who  then  demon-
strated progression of disease. Of importance was the 
need  to  define  the  nature  of  the  mechanisms  asso-
ciated with destruction of existing tumor other than 
that of ADCC, if such existed. Such studies had been 
accomplished in defining the mechanisms for Rituxan 
control of CD-20 expressing cells such as lymphomas 
(7).  
2. Methods 
A.TSA Isolation and characterization 
In the past, we have isolated and characterized 
several  human  tumor  specific  membrane  antigens 
(TSA’s) defining a number of human solid tumor ma-
lignancies.  Because  of  the  low  levels  of  antigen  ex-
pression in any one patient’s tumor, pooled allogeneic 
membrane proteins were employed in evaluating the 
threshold level of antigen necessary to optimize cel-
lular and humoral antitumor responses. Among the 
tumors  studied,  were  those  derived  lung,  co-
lon/pancreas, prostate and ovarian cancers. The spe-
cific TSA’s that were studied (4), were isolated from 
human tumor membranes obtained following surgical 
resection. They were then characterized by separation 
into membrane proteins of different molecular weight 
by Sephadex-200 and further defined after separation 
by discontinuous polyacrilamide gel electrophoresis. 
The nearly purified antigen preparation was then de-
livered as a vaccine to patients with Stage II and III 
malignancies  having  undergone  resection,  in  an  at-
tempt to minimize the incidence of recurrence (IRB 
and FDA approved). Each of these immunogens were 
studied and found capable of turning on both cellular 
and  humoral  immune  responses  in  patients  mani-
festing the specific malignancy. Further study of the 
antigens indicated that each were oncofetal in origin 
and were not usually found to be expressed in normal 
tissue. In fetal tissue they appeared to allow matura-
tion of associated tissues prior to birth. At birth it was 
felt  that  re:methylation  of  the  functional  fetal  gene 
resulted in its silencing and thus effects of the onco-
fetal  protein  were  negated.  Only  after  the  silenced 
gene was found to be reactivated in the adult host, 
probably  as  a  result  of  carcinogenic  reactivation  or 
viral transfection, does one see the tumor oncofetal 
protein expressed in the adult, but this time in a mu-
tated form. A number of attempts have been made in 
the past to define tumor antigens in various malig-
nancies including  colon  cancer.  Those  antigens  that 
have been isolated and characterized by other groups 
have failed to define the immunogens. This appears to 
be due to the extremely low levels of expression in the 
individual malignancy and the need for skin testing 
with  the  isolated  pooled  antigens  to  see  if  DHR  is 
present in the antigen preparation of question. Cati-
mel  et.  al.  described  methods  for  purification  and 
characterization of restricted antigens in normal and 
transformed human colonic epithelium (8). 
In  the  malignant  state,  such  as  in  colon  and 
pancreatic cancer, the tumor variant of the oncofetal 
protein  becomes  expressed  and  defined  within  the 
cytoplasm of the tumor cell to serve as a diagnostic 
marker  as  well  as  a  therapeutic  target.  This  tumor 
protein (TSA) then appears to be chaperoned to the 
tumor membrane where it is shed into the serum. The 
isolation of such immunogenic tumor associated an-
tigens,  while  still  highly  expressed  in  the  tumor 
membrane, was achieved through a process of mem-Journal of Cancer 2010, 1 
 
http://www.jcancer.org 
212 
brane  sonication  of  multiple  specimens,  gel  electro-
phoresis and HPLC. TSA activity was confirmed by 
evaluating  the  delayed  cutaneous  hypersensitivity 
response to an intradermal test dose of antigen. The 
DHR skin test which was approved by the hospital 
IRB allowed patients with the corresponding tumor, 
patients with different malignancies and normals to 
be tested to define specificity as well as to rule our 
cross reactivity. This procedure is no longer allowed 
due to the potential of introducing a virus from one of 
the  donors  into  the  pooled  antigemn  preparation. 
Following this we were able to define an elevation in 
an associated circulating serum IgG1 response that is 
capable  of  targeting  the  TSA  membrane  antigen  in 
patients free of disease, five or more years following 
surgery. This latter response has been noted to persist 
for periods lasting up to 10 years post immunization 
in those patients that have remained free from recur-
rent tumor. Because of the potential problem of uti-
lizing pooled allogeneic material to isolate TSA, the 
FDA  has  restricted  tumor  use  to  the  patient’s  own 
tumor, preparing personalized vaccines. During the 
studies of TSA specificity, it was noted that the im-
mune response required somewhere between 500 and 
1000 µgs plus an adjuvant to result in full immuniza-
tion. It is rare however to find more than 100 µg in a 
patient’s own tumor preparation so that self vaccines 
that have added heat shock protein, dendritic cells or 
various viral preparations to allow full immunization 
to occur, have usually been ineffective. 
Each of the monoclonals that have been devel-
oped in our labs to date, appear to demonstrate a high 
level of ADCC as long as one can identify the presence 
of the target protein in tumor sections derived from 
both fresh and from paraffin blocks using immuno-
peroxidase staining (immunohistochemistry).  
B. Hybridoma development 
Antigens  which  demonstrated  delayed  cutane-
ous hypersensitivity and which proved to have the-
rapeutic efficacy in clinical trials, exhibiting cellular 
and humoral immunity, were used to inoculate mice 
for the production of hybridomas. BALB/c mice were 
immunized by IP injections of 50ug of colon carcino-
ma  TSA  emulsified  in  complete  Freund’s  adjuvant, 
0.1ml  x3.  After  10  days  the  mice  received  an  IV 
booster injection of the same amount of TSA in 0.9% 
NaCl solution. Mice were sacrificed three days later. 
Spleen cells were used for cell fusion. This fusion was 
performed by incubation of 5x107 mouse spleen cells 
with 107 sp2/0-Ag14 myeloma cells in 40% PEG. An 
enzyme linked antibody assay (ELISA) was used for 
the detection of clones producing monoclonal antibo-
dies against the specific TSA’s.  
C. Method used to determine antibody depen-
dent cell cytotoxicity (ADCC ) 
A 4 hr. 51Cr or more recently the 111In release as-
say  was  used  to  measure  antibody  dependent  cell 
cytotoxicity. The target cells, whether colon carcino-
ma,  pancreatic  carcinoma  or  lung  squamous  cancer 
cell  lines,  were  obtained  from  the  American  Type 
Culture Collection (ATCC) in Rockville MD. Target 
cells were labeled with 200 µCi sodium 51chromate or 
the equivalent in radiolabelled indium. In 0.2 ml. fetal 
calf  serum  for  1  hour.  Target  cells,  (1x104  in  50  µl) 
were added to 96 U-bottom wells assay plates con-
taining effector mononuclear cells. Effector to target 
cell  ratios’  of  100,  50,  and  25  were  assayed  in  the 
presence of the mAb of interest compared to normal 
IgG at mAb concentrations of 2.5- 5.O µg/well. The 
plates were incubated for 4 hrs. at 370C. in a humidi-
fied  atmosphere  containing  5%  CO2.  Supernatants 
were  harvested  for  gamma  counting  using  Skatron 
Harvester  Frames.  Experiments  were  carried  out  in 
triplicate. Specific lysis was calculated using the fol-
lowing formula. It appeared that 5.0 ug/well of the 
mAb  produced  optimum  results  and  that  the  100:1 
E:T  ratio  produced  the  highest  range  of  tumor  de-
struction over a 4-6 hr. period of time. This of course 
set the stage for eventual employment of a humanized 
or  chimerized  monoclonal  IgG’s  since  one  had  the 
opportunity to see clinical responses in patients with 
recurrent  disease  where  standard  forms  of  therapy 
had failed. 
             
                                                  
                                               
      
Spontaneous  release  was  determined  by  mea-
suring the radioactivity released from target cells in-
cubated  in  medium  alone.  Total  releasable  radioac-
tivity was obtained after treatment with 2.5% Triton 
X-100. Another method of tabulating data is in terms 
of “lytic units”. Such units can be calculated where 
one  lytic  unit  is  defined  as  the  number  of  cells  re-
quired to lyse 15% of a population of 5 × 103 target 
cells  in  a  6-h  assay.  Lytic  unit  values  are  then  ex-
pressed as mean ± standard error of the mean.  
The MTT assay that is occasionally employed is a 
similar laboratory test for antibody cytotoxicity using 
a standard colorimetric assay (an assay which meas-
ures changes in color) for measuring cellular prolife-
ration  (cell  growth).The  amount  of  yellow  MTT 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) oxidised to purple formazan (see figure) is 
measured  spectrophotometrically.  This  oxidation 
takes  place  only  when  mitochondrial  reductase  en-
zymes are active, and thus conversion is directly re-Journal of Cancer 2010, 1 
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lated to the number of viable cells. The production of 
purple  formazan  in  cells  treated  with  an  agent  is 
measured relative to the production in control cells, 
and a dose-response curve can be generated. We feel 
that the radioactive release assay measuring cytotox-
icity, has proven to be more reliable as well as accu-
rate. We have found the sensitivity for the MTT assay 
not to be as reliable as when we measure isotope re-
lease as an indication of cell death, and as such are 
now employing the  111In release assay routinely. As 
newer  non  isotopic  assays  are  developed  we  do 
however  plan  to  compare  results  with  both  proce-
dures. 
D. Measurement of Apoptosis by Annexin V 
binding 
While the major attack by mAb therapy occurs 
thru ADCC we have defined that other mechanisms 
are involved including an apoptotic event. He, apop-
tosis represents programmed cell death wherein the 
process is characterized by a number of morphologi-
cal and biochemical features including shrinkage of 
cytoplasm, condensation and margination of nuclear 
chromatin, fragmentation of DNA into 120-180 base 
pair  segments,  and  finally  blebing  of  the  plasma 
membrane and formation of apoptotic bodies, which 
are  rapidly  removed  by  neighboring  phagocytes. 
Different  changes  taking  place  on  the  surface  of 
apoptotic  cells  such  as  the  expression  of  thrombos-
pondin binding sites, loss of sialic acid residues and 
exposure  of  a  phospholipid-like  phosphatidylserine 
(PS) have been previously described (9). Phospholi-
pids are asymmmetrically distributed between inner 
and  outer  leaflets  of  the  plasma  membrane  with 
phosphatidylcholine and sphingomyelin exposed on 
the external leaflet of the lipid bilayer, and phospha-
tidylserine predominantly observed on the inner sur-
face facing the cytosol (9).  
3. Results  
In spite of the poor response of recurrent tumors 
to the use of chemotherapy, we now believe that it is 
possible to develop an efficient therapeutic approach 
to the management of many of these malignancies by 
employing specific mAb’s directed against an array of 
immunogenic proteins expressed on their cell surfaces 
(10,11). For the particular group of antibodies that we 
have  developed  to  date as well  as  for  others  being 
developed, all appear capable of initiating destruction 
of existing tumor by the process of antibody depen-
dent cell cytotoxicity (ADCC). Prior to considering the 
therapeutic potential of such antibodies, we analyzed 
their capability for accurately quantifying the inten-
sity of their staining capabilities, and the % of reactive 
cells expressing the relevant cell surface target anti-
gen. The binding of the mAbs have varied with the 
tumor population studied, but combinations of mAbs 
have shown that tumor recognition can be optimized 
to offer a superior response. This procedure has also 
offered a mean density distribution of the antigen so 
that we are able to predict the number of binding sites 
available (12). In this manner we are evaluating the 
procedure for defining antibody therapy; one that can 
be checked for optimum response with each monoc-
lonal  or  group  of  monoclonals  studied.  When  we 
evaluated ADCC as an in-vitro assay for tumor cyto-
toxicity,  we  employed  our  protein  derived  mAb’s, 
demonstrating that these mAbs were associated with 
a 50-60% or better rate of tumor cell destruction. This 
process  was  found  to  occur  in-vitro,  over  a  4-6  hr. 
period of time.  
The  rate  of  destruction  of  tumor  cells  that  we 
used in this assay was defined as noted above, by a 
chromium or indium release assay, wherein the anti-
body specific to a tumor marker expresses its efficacy 
in the presence of human effector cells. We have noted 
that with those antibodies having a low destructive 
rate, especially under 10%, the potential for effecting a 
clinical response in patients is minimal. This is prob-
ably due to the rapid rate of tumor cell proliferation in 
culture,  requiring  destructive  (apoptotic)  rates  in 
excess of a 30% kill in the in-vitro assay before clinical 
evidence of destruction of tumor is seen. Methods for 
regulation of ADCC by improving effector cell func-
tion are being further evaluated (13). 
In  an  analysis  of  the  ability  of  a  carbohydrate 
monoclonal  antibody  such  as  CA  17.1A  to  induce 
apoptosis  in  colon  cancer  cells,  we  compared  that 
mAb to one that was derived from an immunogenic 
glycoprotein (TSA) of colon Ca origin proven to have 
efficacy in clinical trials. Monoclonal antibody 17.1A 
was originally employed in a detailed study of that 
mAb targeting residual colon tumor cells that might 
remain  following  surgery  for  Dukes  C2  carcinoma 
suggesting a marked improvement in the incidence of 
recurrence  when  this  carbohydrate  monoclonal  fol-
lowed  resection  of  disease.  This  monoclonal  (Reit-
mueller) (19) had originally been used in clinical trials 
in Germany suggesting that a clinical response could 
be anticipated when the antibody was added as an 
adjuvant to the surgery of Dukes C2 colon carcinoma. 
A major trial utilizing this monoclonal antibody now 
referred to as Panorex, was run by Glaxo, but prior to 
initiation  of  the  study,  an  ADCC  study  was  per-
formed. The results are seen in Fig. 1.  
 Journal of Cancer 2010, 1 
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Fig.1 Demonstrates the effect of chimerization on the function of mAb 31.1 and the need for an effective E:T ratio. 
 
Needing  a  backup  monoclonal  to  compare  the 
effectiveness ofa tumor kill from mAb 17.1A, Tsang 
utilized mAb 31.1 that had been developed by Tsang 
and Arlen (6). The mAb had been derived from the 
immongenic TSA for colon cancer. Noting a low level 
antitumor response for the 17.1A mAb, that was be-
low 20% tumor kill every 6 hours and especially when 
compared with the results from chimerized mAb 31.1, 
it appeared that 17.1A would not deliver the thera-
peutic response that was hoped for. Fig.1 clearly de-
monstrates the enhanced effectiveness of a chimerized 
immunogenic protein derived mAb. In a similar ap-
proach to the evaluation of the carbohydrate mAbs 
such as Ca19.9 (pancreatic Ca), PSA (prostate Ca) and 
Ca125 (ovary), all demonstrate minimal if any thera-
peutic effect when delivered intravenously to patients 
with metastatic malignancy  
Having identified three separate tumor specific 
antigens  (TSA’s)  expressed  in  colon  and  pancreas 
cancers, we went on to produce monoclonals for each 
target protein via hybridoma production. Following 
this, the heavy and light chains for each mAb were 
defined and transfected into CHO cell lines as noted 
above for production of the chimeric versions of these 
mAbs that is mAbs NPC-1, 31.1 and 16C3.  
With plans for studying the tumor effect of Pa-
norex in patients having undergone Dukes C2 colon 
resection, requests were made for in-vitro data to be 
obtained.  ADCC  as  such  was  carried  out  by  Tsang 
and mechanisms of action studied (14). A control for 
comparing Panorex, mAb 17.1A, to a monoclonal that 
shown activity in previous studies, that is mAb 31.1 as 
mentioned above, was employed. The data from this 
study is illustrated in Fig.1. It was apparent that tu-
mor destruction by a carbohydrate monoclonal was 
not that efficient even when compared to a murine 
mAb derived from a tumor associated immunogenic 
protein. The use of the chimeric version of the mAb 
31.1 clearly illustrated the benefit of employing this 
class  of  mAb’s  that  were  optimized  to  deliver  the 
highest rate of tumor kill. At this point mechanisms 
by which the mAbs functioned to control tumor were 
studied in detail, Tsang et al. (14). 
A number of studies were performed with the 
mAb 31.1 to evaluate potential efficacy. Cell flow cy-
tometric  data,  followed  by  ADCC  and  Annexin  V 
binding were used to lead up to animal studies for 
evaluating  efficacy.  Of  interest  as  the  study  pro-
gressed. was that when the target proteins were eva-
luated as to time of expression, it was found that those 
cells undergoing genotypic transformation could be 
shown to express the target protein 3-4 months prior 
to  the  phenotypic  appearance  of  malignancy.  This 
made the proteins being evaluated to be ideal tumor 
markers when expressed, and paved the way for the 
development of early diagnostic tests by IHC as well 
as in ELISA serum assays. 
The rationale for testing various effector to tu-
mor cell ratios in the ADCC study reflects that the true 
effector cell presence in a population of human peri-
pheral blood mono nuclear cells (PMNC), is defined 
by  a  specific  subset  within  the  effector  cell  group, 
those  expressing  CD16  surface  marker.  A  proper 
number of such cells must be present in order to in-
duce the release of products initiating cell cytotoxici-
ty. It appears that the primary effector cell responsible 
for inducing the ADCC response is the NK cell. When 
this cell population, containing ligands for the human 
Fc receptor is delivered with an effective monoclonal 
antibody  to  the  tumor  cell  surface  expressing  the 
proper TSA, there is an apparent release of NO which 
initiates  the  cytotoxic  process  In  the  in-vitro  model 
one finds that the effector cell to tumor cell ratio must 
be maintained at 80:1 to 100:1 for optimum efficacy. Journal of Cancer 2010, 1 
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Fig. 1 denotes that as the ratio of E:T decreases, 
the  effective  response  is  halved.  It  is  also  apparent 
that  when  the  antibody  is  chimerized,  allowing 
proper exposure to the human Fc receptors, there is an 
increase  in  response  which  results  in  an  improved 
destruction of the tumor population.  
Tsang et. al. (14) evaluated the use of hrIL-6 as a 
means  of  enhancing  the  ADCC  response.  PMNC 
(polymorphonuclear  cells)  were  preincubated  in 
100-400 u/ml. of the lymphokine. The effect was to 
significantly enhance the activity of ADCC as long as 
the proper mAb was employed; one that defined the 
tumor immunogenic protein. Depletion of the CD16 
population of PMNC suggested that these were the 
responsible  cells  for  the  IL-6  augmentation  and  as 
such the NK cells were the prime candidates for the 
mAbs  to secondarily induce  tumor  cell  destruction, 
rather than that of a direct effect of the mAb on the 
tumor. 
In  evaluating  the  specificity  of  the  ADCC  re-
sponse  to  several  tumor  types  and  to  controls,  our 
prime candidate at the time was chimeric mAb 31.1. 
The  other  mAbs  being  studied  against  colon  and 
pancreas cancer are being prepared for chimerization 
in  a  high  expression  vector  to  attempt  to  achieve 
production  levels  above  1000mg./L  Chimeric  31.1 
was the only potential antibody available for study 
and to compare to CA 19.9, a carbohydrate monoc-
lonal antibody showing activity in pancreatic neop-
lasms as well as some colorectal lesions. UPC-10, a 
myeloma antibody was used as the control. One can 
see relatively good function of mAb 31.1 against colon 
and  pancreas  when  compared  to  CA19.9.  UPC-10 
represented the negative control, Tables 1 and 2.  
Table 1. In-111 labeled target cells, antibodies used at 5 ug/ml, human PBMC used as effector cells, 4 hour incubation at 
37
0C before harvest. 
Target  Effector:Target Ratio  % Specific ADCC Activity (± SEM) 
  mAb 31.1chi  CA 19-9  UPC-10 negative cntl 
SW1463 
(colorectal adeno) 
100:1  51.0 ± 1.3  2.0 ± 1.2  3.4 ± 0.8 
  50:1  36.0 ± 1.0  1.9 ± 0.1  1.1 ± 0.8 
  25:1  24.4 ± 1.7  1.6 ± 0.3  1.3 ± 0.2 
AsPC-1 
(pancreas adeno) 
100:1  30.3 ± 1.3  19.5 ± 0.4  3.2 ± 0.9 
  50:1  19.3 ± 1.3  1.4 ± 0.4  0.6 ± 0.5 
  25:1  12.7 ± 0.1  3.3 ± 1.1  -0.6 ± 1.9 
H441 
(lung epithelial ) 
100:1  5.0 ±0.4  0.6 ± 3.0  3.0 ±1.2 
  50:1  5.2 ± 3.6  1.8 ± 0.6  -0.5 ± 0.4 
  25:1  6.7 ± 0.6  1.0 ± 0.2  0.1 ± 0.5 
MCF-7 
(breast adeno) 
100:1  2.4 ± 0.3  2.5 ± 0.5  2.6 ± 0.8 
  50:1  2.4 ± 0.5  1.7 ± 0.1  1.8 ± 0.3 
  25:1  2.8 ± 0.4  2.5 ± 0.2  1.7 ± 0.1 
 
 
 
 
 
Table 2 Chimeric 31.1 in a 
secondary study indicates the 
strong ADCC activity of mAb 
31.1 against colon and pan-
creatic Ca. 
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Regardless of the array of different mechanisms 
involved in initiating tumor cell death thru intraven-
ous administration of an effective IgG, the appropri-
ate monoclonal antibody required is best delivered in 
the chimeric or humanized form. Here the presence of 
the  human  Fc  component  of  the  specific  IgG  em-
ployed always contains the NK receptors which op-
timizes the transfer of this cytotoxic cell to the surface 
of the tumor. At that point NO can be released at the 
site on the membrane where the antibody binds re-
sulting in the phenomenon of ADCC. It is also sus-
pected that in those instances where tumor dormancy 
occurs, that the NK cell may release nitric oxide syn-
thase which potentially suppresses kRas function to 
initiate the process of dormancy.  
In order to evaluate the potential for a clinical 
response initiated by those mAb’s that we were in-
terested  in and  which  were  derived  from  immuno-
genic  proteins,  an  in-vivo  murine  model  was  de-
signed. We chose a therapeutic situation to evaluate 
the effect of the antibody on fully established tumors 
in mice. Control animals (nude mice) were primed by 
injecting 2 million of either human colon adenocarci-
noma  or  pancreatic  adenocarcinoma  cells  (obtained 
from ATCC) into the hind legs of the animals. Each 
animal (7per group) were studied for the appearance 
and progression of tumor cell growth. At 10 days fol-
lowing innoculation, clinical tumor masses appeared 
from 2-3 cm in diameter and progressed so that within 
10 to 15 days each animal was limping and having 
difficulty in functioning. At the end of following week 
each animal appeared pre terminal. The experiment 
was then repeated, to test the ability of the monoc-
lonals to control tumor growth by indicating regres-
sion of the established tumor mass.  
Groups  were  divided  to  receive  the  2  million 
cancer cells noted above, by subcutaneous injections 
in  the  leg.  On  the  10th  day  of  the  experiment  one 
group was given 400µgs of non specific human IgG 
with human effector cells intraperitoneally.  
This was performed as a negative control to rule 
out the ability of nonspecific IgG in the presence of 
effector cells to elicit an apoptotic effect on the grow-
ing human tumor. A second injection of antibody was 
given on day 11. The second group that received tu-
mor cells was given the therapeutic antibody, mAb 
31.1 without the potential benefit of effector cells. This 
second arm was  employed to evaluate if any addi-
tional mechanism other than NK cell activity induced 
tumor  destruction.  The  third  group  received  both 
intraperitoneal mAb plus human effector cells. It be-
came readily apparent that without the proper mAb, 
non specific human IgG in conjunction with human 
effector cells had no response on tumor growth and 
the masses appearing on the animals’ upper leg con-
tinued  progressing.  Therapeutic  monoclonals  given 
without  effector  cells  did  have  some  capability  of 
controlling  growth  of  tumor  suggesting  that  a 
“second”, but lesser mechanism than ADCC might be 
coming into play. We suspect that many of these the-
rapeutic mAbs secondarily act as TRAIL ligands in-
itiating  apoptosis  defined  by  annexin  V  binding. 
When the more detailed animal study was performed 
evaluating mAb 31,1 alone and in combination with 
effector cells further information was gained on the 
ability  of  these  TSA  monoclonals  to  initiate  tumor 
destruction thru a number of different means includ-
ing its primary function in ADCC, Figs. 2,3,4. 
Realizing  that  one  mechanism  (ADCC),  might 
not completely explain the ability of protein derived 
monoclonals to control human tumor growth, espe-
cially after seeing some weak response in the absence 
of effector cells, we examined the effect of this group 
of mAbs on the induction of apoptosis as defined by 
annexin V binding. At the time of cell death, just prior 
to DNA destruction by the apoptosome, phosphoino-
sityl serine is transported to the surface of the tumor 
cell  membrane  where  it binds  to  annexin V  tagged 
with a fluorescent signal.  
 
 
Fig. 2 Control arm using normal IgG to replace the the-
rapeutic effect demonstrating that the addition of effector 
cells can alter the growth of tumor cells. Journal of Cancer 2010, 1 
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Fig. 3 Some control of tumor growth is seen when a po-
tentially therapeutic antibody 31.1 is delivered in the ab-
sence of human effector cells. 
 
 
 
Fig. 4 Defines the ability of an effective human IgG1 (TSA 
derived 31.1 given in combination with human effector cells 
to control growth of human cancers. 
 
The results of the shift in phosphoinosityl serine 
to the outer cell membrane are seen in Figs.5 and 6 - 
where treated and untreated  pancreatic cancer cells 
were compared for the degree of annexin V binding. 
 
 
 
Fig. 5 Results of annexin V binding on untreated cells. 
 
 
 
Fig. 6 Effect of mAb 31.1 treatment on Annexin V binding 
of pancreatic cancer cells. 
 
Examination of the 2 scattergrams indicates that 
in the 4 quadrants illustrated by Figs 5 and 6, that the 
left lower quadrant represents the population of live 
cells.  The  right  lower  quadrant  expresses  the  inci-
dence of early apoptotic cells before and after induc-
tion by mAb therapy and the right upper quadrant, 
the later apoptotic or necrotic cells that begin to ap-
pear. As such, the degree of binding based on shift to 
the right quadrant (lower and upper) of the scatter-
gram indicates that the % of annexin + cells in the 
untreated group was 18.22%. This was found to have Journal of Cancer 2010, 1 
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increased to 36.83% of the cells undergoing apoptosis 
in the treated group. This possibly explains the shift 
we see in the animal model curve, where the mAb 
alone was used without effector cells being present. 
Additional  possibilities  arise  as  to  other  me-
chanisms  by  which  therapeutic  mAbs  effect  tumor 
growth. We evaluated the effect of this group of TSA 
mAb’s on VEGF expression and were able to demon-
strate  a  significant  diminution  in  the  level  of  these 
surface growth factors similar to what is seen with 
Herceptin (Table 3). 
 
Table 3. Antibody suppression of VEGF by both 31.1 and Herceptin. 
 
 
 
4. Discussion 
The ability to employ passive immunization, that 
is, mAb therapy, alone or in combination with che-
motherapy has become a valid approach for manag-
ing patients with malignancies that have failed stan-
dard chemotherapy. While most of those antibodies 
used in the treatment of malignancies are presently 
targeting growth factors, we believe that antibodies, 
IgG1’s,  directed  against  immunogenic  proteins  ex-
pressed on the tumor cell surface membrane, offer a 
greater  potential  for  effective  tumor  control  in  the 
metastatic setting.  
Liu et al. (15) noted the presence of tumor asso-
ciated antigens on the cell surface of malignant lesions 
as characteristic of many cancers. They reported that 
antibodies to these TSA’s could be developed and that 
it might be possible to use such antibodies for target-
ing the specific tumors. They used replacement of the 
mouse  constant  C  domain  regions  with  the  corres-
ponding  human  equivalent  (human  Fc)  to  create 
chimeric mAbs. Antibodies obtained by this approach 
retained specificity for antigen but were felt to be less 
immunogenic if they were given to patients.  
In  general,  the  present  approach  we  are  em-
ploying and that is required for developing such an-
tibodies for therapeutic use in patients requires that 
the IgG be humanized or human in structure. In ad-
dition  the  expression  of  the  monoclonal  should  be 
produced in a mammalian cell line such as CHO (dhfr 
-) and for commercial value, the antibody should be 
expressed at over 1000 mg/L of bioreactor fluid that 
contains no fetal calf serum.  
The mouse mAb L6 (IgG2aK) that Liu’s group 
studied  binds  to  a  carbohydrate  antigen  that  is 
present at the surface of cells from such human car-
cinomas  as  lung,  breast,  colon,  and  ovary.  L6  was 
found to mediate CDC (complement-mediated cyto-
toxicity)  with  human  complement  or  ADCC  with 
human  effector  cells.  cDNA’s  encoding  the  immu-
noglobulin  genes  for  L6  were  isolated.  Restriction 
enzyme recognition sites were created in the cDNA 
sequences at the V/C junction by in-vitro mutagenesis 
using oligodeoxy- ribonucleotides. The chimeric an-
tibody  they produced  was  then  compared  with  the 
mouse L6 for effector function. It was founds to bind 
to tumor cells as well as the mouse L6 antibody but 
was more active in ADCC, killing a greater number of Journal of Cancer 2010, 1 
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target cells at a concentration lower by a factor of 100. 
The chimeric mAb that was produced was never de-
veloped for clinical testing. Other mAb’s such as A33 
were also tested clinically but did not reach the the-
rapeutic effect felt necessary for commercialization. 
We realized the need for the chimerization of our 
monoclonal  antibodies,  with  the  concept  that  if  the 
human anti-mouse antibody (HAMA) responses were 
high with the murine hybridoma version, humaniza-
tion might be indicated both for enhancement in re-
sponse and for minimization of the HAMA response. 
In a single patient study with the chimeric version of 
our monoclonal 31.1 directed against hepatic metas-
tasis  from  pancreatic  cancer,  the  HAMA  response 
became  minimally  elevated  in  contrast  to  pretreat-
ment levels. After 2 doses of the chimeric mAb at 25 
mg and 50 mg IV the serum marker for Ca 19.9 fell 
from 3000U to 300U. The HAMA prior to therapy was 
5  nanogms/ml  prior  to  administration  of  the  mAb 
and rose to 7 nanogms/L 2 weeks after the second 
and final dose was given. Additional mAb was not 
available for further study. We are presently prepar-
ing  a  new  version  of  our  mAbs  derived  from  the 
original immunogens used in clinical trials. It is being 
cloned into a vector with a strong promoter capable of 
delivering the anticipated 1000 mg/L or more, needed 
for production as a GMP product.  
Where  the  need  to  minimize  the  HAMA  re-
sponse is important, it can be accomplished by mod-
ifiying the structure of the mAbs utilizing the back-
bone structure of the human FAb in the humanization 
process  leaving  only  the  murine  CDR  loops.  This 
modificatyion  in  structure  results  in  reduction  in 
HAMA response however it may not be as important 
as the therapeutic efficacy of the antibody being em-
ployed in its chimeric form.  
A  secondary  host  response  contributing  to  the 
potential  efficacy  of  the  mAb  may  be  seen  in  the 
production of an anti-idiotype response to the thera-
peutic monoclonal (16). As part of the hypothesis of 
an antiidiotype network, immunization with a given 
TSA  generates  production  of  antibodies  mAb1.  In 
turn, Ab1 will initiate production of a series of aniti-
diotype  antibodies  termed  Ab2  which  express  the 
internal image of the TSA. Some of the Ab2 molecules 
can effectively mimic the 3 dimensional structure of 
the  TSA.  These  particular  antibodies  can  induce  a 
specific immune response similar to the original TSA. 
This particular antiidiotype antibody, the Ab2, struc-
turally represents an exogenous peptide that can be 
endocytosed by the APC’s and degraded into 14-25 
mer peptides to be presented by class II antigens to 
activate CD4 helper cells. Cross presentation to CD8+ 
T cells also occur. We are now in the process of de-
veloping the procedures to define and quantify the 
appearance of the anti id response to the clinical de-
livery of our NPC-1 and 31.1 chimeric monoclonals. 
When entering clinical trials we plan to measure le-
vels of anti-idiotypes appearing in the serum in re-
sponse to mAb’s NPC-1, 31.1, and 16C3. If enhance-
ment in immune responses are noted in relation to 
MHC  Calss  1,  it  will  be  important  to  determine  if 
mAb2  does  mimic  the  mirror  image  of  the  antigen 
used in the development of our monoclonals and if 
Ab2 in of itself has the immunogenic capabilities to 
generate cytotoxic T-cells. The failure of previous at-
tempts to produce effective antiidiotypic monoclonals 
resided in the fact that the monoclonals being studied 
were  carbohydrate  in  origin.  As  such  any  anti  idi-
otype response would theoretically mimic the carbo-
hydrate moiety of the antigen. 
The  first  monoclonal  antibody  technology  was 
introduced  in  1985  with  the  introduction  of  OKT3 
(17). This antibody was developed against an epitope 
on the epsilon unit within the CD3 complex. It proved 
to be a potent immunosuppressive agent, capable of 
minimizing allograft rejection in heart, lung and kid-
ney  transplant.  In  1989  Meldstedt  (18)  at  the  Karo-
linska  Institute  tested  the  first  potential  antitumor 
antibody Ca 17.1A for its activity in metastatic colon 
Ca. He noted regression of metastatic lung lesions, but 
no prolongation in survival. As such the monoclonal 
was discontinued in therapeutic trials. Reitmuller (19) 
later  suggested (1994)  that  marked  improvement  in 
the  survival  of  Dukes  C  colon  cancer  could  be 
achieved using monoclonal 17.1A in the adjuvant ra-
ther than therapeutic setting. This finding however, 
was  not  confirmed  in  more  extensive  clinical  trials 
carried  out  in  the  US  using  17.1A  under  the  name 
Panorex as described previously. We had anticipated 
minimal anti-tumor activity for Panorex since it was 
carbohydrate  in  origin,  and  as  with  other  carbohy-
drate mAbs, apoptosis if present, was usually minim-
al. On completion of a detailed 5 year clinical study 
employing Panorex in patients with Dukes C carci-
noma, no clinical improvement was found. As such 
this mAb was removed as potential clinical reagent 
for  use  in  locally  advanced,  recurrent  and  possible 
metastatic colon cancer. 
Most therapeutic mAbs with human backbones 
are of the IgG1 isotype which effectively mediate the 
Fc domain based function, including compliment fix-
ation and ADCC. Other isotypes such as the IgG2’s 
have been used when the mAb was designed to act 
simply  thru  its  antigen  binding  capabilities  rather 
than have the inherent capability of working to induce 
apoptosis. Examples of the latter category include the 
anti-EGF monoclonals, Cetuximab(Erbitux)(20), Her-Journal of Cancer 2010, 1 
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ceptin(21)  and  Bevacizumab(Avastin)(22)  which  are 
murine/human chimeric antibodies. We have found 
that by humanizing the Fc portion of our antibodies, 
we almost double the ability to destroy tumor growth, 
probably reflecting the presence of the proper ligands 
on the human Fc for ADCC as well as the initiation of 
complement fixation. While we understand that those 
mAbs that address the issue of a human epidermal 
growth factor have some effect on clinical response, 
these mAb’s eventually lose control of tumor growth 
with subsequent progression ofdisease as a result of 
the tumor finding another metabolic pathway for its 
growth  and  development.  Where  Avastin  was  be-
lieved to function through diminution in the vascular 
supply to the tumor, it is now thought that this agent 
may affect microcirculation within the tumor making 
the introduction of chemotherapeutic agents in com-
bination  with  the antibody  more  effective  in  tumor 
destruction. 
Whereas tumor growth in the case of pancreatic 
cancer having recurred, has an average response to 
the chemotherapeutic agent Gemcitabine of 7 months, 
few  agents  have  improved  on  this.  Tarceva  when 
added to a gemcitabine regimen does appear to have a 
slight advantage of 14 or so days. When Avastin was 
added to the Gemcitabine protocol for recurrent pan-
creatic cancer there was no evidence that any efficacy 
could  be  determined.  We  do  however  believe,  that 
those  monoclonals  that  have  been  derived  from  an 
immunogenic target in pancreatic and or colon cancer 
such as TSA NPC-31.1, when employed alone or in 
combination  with  chemotherapy,  may  show  a  sur-
vival advantage in those recurrent malignancies hav-
ing failed standard chemotherapy.  
In  the  initial  chimerization  of  our  protein  de-
rived mAbs, we chose a vector which allowed inser-
tion of both heavy and light chain genes with trans-
fection  to  CHO  cells  for  optimum  production.  The 
plasmid vector pRc/CMV that we employed was de-
signed with the intent of achieving high expression of 
our chimeric monoclonal antibodies. The vector had a 
cloning site which accepted the heavy and light chain 
genes, inserting them downstream from the human 
CMV. The vector allowed antibody to be produced at 
levels greater than 100mg/L in bioreactor media, so 
that  therapeutic  doses  of  250-500mg,  could  be  deli-
vered.  
We  do  believe  that  with  mAbs  demonstrating 
minimal HAMA and high levels of ADCC, that doses 
of 200mg. to 400mg.delivered every two weeks I.V. 
could be effective in controlling metastatic cancer. At 
the  present  time  we  have  chosen  a  newer  vector 
which  allows  similar  insertion  of  heavy  and  light 
chain  genes,  but  has  a  potential  for  production  in 
excess of 1000 mg/L of bioreactor fluid. Both plasmid 
vectors carry a dhfr expression unit driven by an en-
hancer-deficient SV40 early promoter. The vector is 
inserted into the CHO-D-SFM (dihydrofolate reduc-
tase (dhfr)-deficient Chinese hamster ovary) cells in 
near serum-free medium supplemented with 1 g/ml 
of MTX. At the end of the production, cells have to be 
adapted to serum free media before final purification 
of the antibody can occur. 
ADCC as we have described above, appears to 
be one of the important mechanisms for tumor cell 
lysis of unconjugated mAb’s. Many of these antibo-
dies having high affinity and specificity do not elicit a 
strong  lytic  response.  These  monoclonals  contain  a 
conserved N-linked glycosylation site in each of the 
CH2  domains  of  the  constant  region.  The  sites  are 
normally  occupied  by  complex  oligosaccharide 
structures which have an important effect on the ac-
tivity of the mAbs. One of the qualitative differences 
in  the  oligosaccharide  component  between  human 
circulating antibodies and those derived from recom-
binant antibody producing cell lines, is the presence 
of  bisected  oligosaccharides  on  the  naturally  occur-
ring antibodies. These oligosaccharides are produced 
by  a  reaction  catalyzed  by  N-acetylglucosaminyl 
transferase  III  (GnTIII)  which  essentially  is  not  ex-
pressed  in  the  commercially  produced  mAbs.  The 
effect of GnTIII was assessed in terms of the potential 
enrichment of humanized therapeutic mAb’s (23). The 
ADCC activity of three independent antibodies was 
substantially increased, ten to one hundred fold when 
the  antibodies  were  derived  from  cell  lines  overex-
pressing GNTIII. Based on the final ADCC levels that 
we  have  defined  with  our  mAbs,  we are  now  eva-
luating the possibility that alteration in glycosylation 
patterns can further enhance ADCC to yield higher 
therapeutic responses. 
The  first  therapeutic  mAb  to  receive  FDA  ap-
proval, Rituximab, was for use in the low and inter-
mediate grade lymphomas. This monoclonal product, 
developed  at  IDEC,  is  a  naked  antibody  directed 
against the surface antigen, CD20. Many of the me-
chanisms of activity have been defined (5). This is of 
importance to our group since we are still defining the 
multiple methods for tumor destruction initiated by 
those  monoclonals  derived  from  immunogenic  pro-
teins expressed on the surface of the tumor cell. The 
CD20  antigen  seen  on  all  lymphocytes  and  most 
lymphoma cells proved to be a transmembrane pro-
tein of 297 amino acids. While not serving as a surface 
immunogen,  the  binding  of  CD20  by  Rituxan  did 
prove to initiate apoptosis. The intracellular portion of 
the CD20 antigen was shown to contain phosphoryla-
tion sequences for protein kinase C, calmodulin, and Journal of Cancer 2010, 1 
 
http://www.jcancer.org 
221 
casein kinase –2. When CD20 is transfected into the 
cell,  intracellular  Ca++  increases.  When  Rituxan  at-
tacks or cross links to CD20 there is an increase in 
intracellular Ca++ and further phosphorylation of the 
inner  chain  of  CD20.  There  is  also  an  associated 
upregulation of C-myc and an upregulation of MHC-2 
proteins. 
Caspace 3 is activated in the above mechanism of 
Rituxin/CD20 binding to induce apoptosis in inter-
mediate grade lymphoma. This has resulted in one of 
the more active approaches to the treatment of a he-
matologic malignancy. CD20 has a 95% expression in 
B cell malignancies explaining the high incidence for 
potential cases to be treated.  
In  those  cases  where  commercial  monoclonals 
target  surface  growth  factors  such  as  epidermal 
growth factors (Erbitux, Herceptin), the incidence of 
expression  of  these  growth  factors  for  many  of  the 
patients  is  in  the  20%  range,  explaining  the  low 
number of patients with colon and breast cancer that 
can be subjected to effective treatment.  
One  year  survival  with  Rituxan  in  lymphoma 
has been shown to be 69% and for 2 year 67%. When 
delivered  with  chemotherapy,  the  survival  results 
have  increased.  This stands  in  contrast  to  the  com-
mercial  growth  factor  mAb’s  noted  above,  such  as 
Erbitux,  Herceptin  and  Avastin  where,  as  noted 
above, enhanced survival is defined in months even 
when given in combination with chemotherapy (2). 
We anticipate that the protein based mAb’s that we 
have been developing should demonstrate responses 
in solid tumor malignancies similar to what is seen for 
lymphoma patients, when Rituxan is employed. With 
further analysis of our protein based mAbs we believe 
that a number of additional mechanisms will be de-
fined in addition to those of ADCC, apoptosis as de-
fined by annexin V binding and suppression of VEGF 
to minimize vascularity to the tumor. We believe that 
this class of TSA derived mAbs have the potential to 
further improve results expected to be obtained when 
the naked antibody is used. When given in combina-
tion with immune stimulants and then chemotherapy 
is used for additional treatment, one can anticipate a 
further improvement in survival. 
Mechanisms defining the action of NK cells are 
being resolved especially in terms of their relationship 
to the Fc component of the IgG as noted above. This 
pertains to receptors that are essential for initiating 
the ADCC process and are potent regulators of the 
ADCC.  Inhibitory  Fc  receptors  have  been  found  to 
modulate  in-vivo  cytoxicity  against  tumor  targets 
(24).  
The inhibitory FcγRIIB molecule is an important 
part of the activator suppressor system. The FcγRIII 
receptor enhances the activity of the effector cell de-
fining the associated ligand on the IgG. The antitumor 
activities of therapeutic antibodies include blocking, 
signaling pathways, activation of apoptosis, effector 
cell  mediated  cytotoxicity,  and  engagement  of  Fc  γ 
receptors on effector cells. It’s been shown that Her-
ceptin  (Trastuzumab)  and  Rituxan  (Rituximab)  en-
gage both activation with Fc γ III, as well as inhibition 
with the Fc γ IIB antibody receptor on myeloid cells. 
Negative signals can down-regulate T, B, monocytes, 
dendritic  cells  as  well  as  NK  cells  functions.  These 
signals belong to numerous subfamilies but we focus 
on the inhibitory receptors of the B7 family. However 
other negative regulators are also important such as 
the FcRIIB, CD22 and others.  
Human Natural Killer Cells express only the A 
(transmembrane)  iso  form  of  CD16.  This  facilitates 
activation of the NK cell. ADCC has been viewed as a 
mechanism  to  directly  induce  a  variable  degree  of 
immediate tumor destruction. This process looks to 
antigen presentation and induction of tumor directed 
T cell responses.  
With regard to complement fixation cytotoxicity, 
the IgM’s have the most effective method for induc-
tion of cell death. However because of the size of the 
molecule, it has little therapeutic effect since it is dif-
ficult for this IgG to penetrate those vascular struc-
tures  needed  to  reach  the  tumor.  This  is  why  the 
proper antibody for therapy must not only have tu-
mor killing capability, and induce apoptosis, but be 
capable of reaching the target cells with ease. These 
tasks  can  be  accomplished  more  readily  with  the 
IgG1’s and 3’s. Isotyping those clinical antibodies that 
we have seen to be potent in the in-vitro as well as 
in-vivo situation still indicate that the IgG1’s have the 
greatest versatility to enhance immune reactivity.  
5. Conclusion 
What  appears  unique  to  those  immunogenic 
TSA protein derived antitumor mAb’s, in comparison 
to  those  directed  against  surface  epidermal  growth 
factors (EGF-1, EGF-2,VEGF), is their specificity to the 
malignancy only as well as high rate of tumor kill in a 
relatively short period of time. This obviates the need 
for long clinical trials attempting to illustrate an im-
provement in the interval to progression of the me-
tastatic disease process.  
The  apoptotic  effect  which  occurs  in  6-8  hrs 
when these proteins derived mAbs are employed via 
intravenous administration is defined by ADCC me-
diated by the recruitment of NK, CD-16 cells. There is 
also  a  suggestion  of  inhibition  in  the  expression  of 
VEGF and that a degree of apoptosis seen in the ab-
sence of NK cells may be mediated by TRAIL ligation. Journal of Cancer 2010, 1 
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This same group of TAA derived antibodies appears 
to demonstrate an ability to define target antigens as 
diagnostic  molecular  markers,  months  before  the 
phenotypic  expression  of  malignancy  becomes  ap-
parent. A requirement for employment in the metas-
tatic situation is defined by the need to demonstrate 
that the target immunogenic antigen is expressed in 
the tumor and specifically on the cell surface mem-
brane where it eventually sheds into the serum. We 
have been able to illustrate that tumor antigen (TSA) 
is routinely shed into serum as a potential diagnostic 
marker and as such are developing a serum ELISA to 
use not only for monitoring clinical responses but as a 
potential diagnostic serum test. 
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